Systemic effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the blood proteome
Kerstin Fentker, Marieluise Kirchner, Matthias Ziehm, Sylvia Niquet, Oliver Popp, Julia Duerr, Laura Schaupp, Jobst Fridolin Roehmel, Stephanie A. Thee, Susanne Hämmerling, Olaf Sommerburg, Mirjam Stahl, Simon Y. Graeber, Marcus Alexander Mall, Philipp Mertins
This study uses proteomics to compare the systemic effects of two CFTR modulator therapies in CF patients, finding that ELX/TEZ/IVA leads to proteome changes closer to healthy profiles.
bioRxiv · Oct 18, 2024 · PreprintMolecular Biology